{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:44:30Z","timestamp":1790959470481,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403899"],"award-info":[{"award-number":["82403899"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203646"],"award-info":[{"award-number":["82203646"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82403899"],"award-info":[{"award-number":["82403899"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["82203646"],"award-info":[{"award-number":["82203646"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015083","name":"Peking University People\u2019s Hospital Research and Development Fund","doi-asserted-by":"publisher","award":["RDXL-2025-13"],"award-info":[{"award-number":["RDXL-2025-13"]}],"id":[{"id":"10.13039\/501100015083","id-type":"DOI","asserted-by":"publisher"}]},{"award":["RDXL-2025-13"],"award-info":[{"award-number":["RDXL-2025-13"]}],"id":[{"id":"https:\/\/ror.org\/035adwg89","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018543","name":"Natural Science Foundation of Tibet Autonomous Region","doi-asserted-by":"crossref","award":["XZZR202402044(W)"],"award-info":[{"award-number":["XZZR202402044(W)"]}],"id":[{"id":"10.13039\/501100018543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Uterine sarcomas are rare, heterogeneous malignancies with distinct pathological behaviors. This study aimed to identify clinicopathological characteristics, prognostic risk factors, and potential therapeutic targets to enhance clinical management. Methods: A retrospective analysis was conducted on 148 patients with uterine sarcoma treated at Peking University People\u2019s Hospital between 1996 and 2025. Clinical outcomes, pathological subtypes, and immunohistochemical profiles were assessed. Additionally, bioinformatics analyses from RNA bulk sequencing of GEO datasets (GSE87581, GSE85383, GSE222045 and GSE64763) were performed to elucidate molecular characteristics across subtypes. Results: The most prevalent subtypes were uterine leiomyosarcoma (uLMS; 38.5%) and low-grade endometrial stromal sarcoma (LG-ESS; 29.7%). The 5-year recurrence rate was 50.5%, with frequent metastases to the pelvis and lungs. LG-ESS demonstrated the most favorable 5-year survival rate (90.3%), significantly higher than that of uLMS (61.8%) and undifferentiated uterine sarcoma (50.0%). Multivariate analysis identified histological subtype, stage, and coagulative necrosis as independent prognostic factors for overall and progression-free survival. Transcriptomic profiling revealed immunosuppression (CSF1R\/CSF3R expression) in high-grade ESS, while uLMS exhibited activation of cell cycle and homologous recombination pathways. Conclusions: Histological subtype, stage, and coagulative necrosis were critical prognostic factors in uterine sarcoma. The findings suggest that vigilant pulmonary surveillance and further investigation into tailored therapeutic strategies may be warranted-including endocrine therapy for hormone-receptor-positive tumors, immunotherapy for high-grade ESS, and PARP inhibitors for uLMS. However, these hypotheses require thorough preclinical and clinical validation. Additionally, caution should be exercised to avoid overtreatment of chemotherapy in early-stage uLMS.<\/jats:p>","DOI":"10.3390\/cancers18111689","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:14:52Z","timestamp":1779452092000},"page":"1689","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Subtype-Specific Prognosis, Recurrence Patterns, and Molecular Features in 148 Chinese Uterine Sarcomas: A Real-World Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Ting","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3575-7838","authenticated-orcid":false,"given":"Xinyu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital, Beijing 100044, China"},{"name":"Department of Statistics, Eberly College of Science, The Pennsylvania State University, State College, PA 16802, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqiao","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuling","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-5133","authenticated-orcid":false,"given":"Guo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2022.07.031","article-title":"Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group","volume":"167","author":"Croce","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00292-022-01072-6","article-title":"Endometriale und weitere seltene uterine Sarkome: Diagnostische Aspekte im Kontext der WHO-Klassifikation 2020","volume":"43","author":"Mayr","year":"2022","journal-title":"Pathologe"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13000-024-01517-x","article-title":"Clinicopathological characteristics and prognosis of uterine sarcoma: A 10-year retrospective single-center study in China","volume":"19","author":"Wang","year":"2024","journal-title":"Diagn. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.7150\/ijbs.39773","article-title":"A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China","volume":"16","author":"Li","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.7150\/ijms.93464","article-title":"Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas","volume":"21","author":"Guo","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11864-024-01214-3","article-title":"Current Treatment Options: Uterine Sarcoma","volume":"25","author":"Lewis","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2147\/IJWH.S536899","article-title":"Prognostic Factors and Role of Pelvic Lymphadenectomy in Patients with Uterine Sarcoma: A Multi-Center Population-Based Cohort Study","volume":"17","author":"Zhuo","year":"2025","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/JS9.0000000000001146","article-title":"Prognosis of uterine and extrauterine low-grade endometrial stromal sarcoma: An observational cohort study","volume":"110","author":"Dai","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wang, F., Dai, X., Chen, H., Hu, X., and Wang, Y. (2022). Clinical characteristics and prognosis analysis of uterine sarcoma: A single-institution retrospective study. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10129-x"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/JCMA.0000000000000242","article-title":"Uterine sarcoma: An unusual but high lethal disease of gynecological malignancies","volume":"83","author":"Lee","year":"2020","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yoshida, R., Takagi, K., Yasui, K., Hioki, M., Okabayashi, T., Kojima, T., Endo, Y., Nobuoka, D., Sui, K., and Inagaki, M. (2026). Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Cancers, 18.","DOI":"10.3390\/cancers18071181"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3349\/ymj.2019.60.6.517","article-title":"Assessing the Optimal Cutpoint for Tumor Size in Patients with Lung Cancer Based on Linear Rank Statistics in a Competing Risks Framework","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12957-020-01963-z","article-title":"Reclassification of tumor size for solitary HBV-related hepatocellular carcinoma by minimum p value method: A large retrospective study","volume":"18","author":"Liu","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-22-0100","article-title":"Aberrant Activation of Cell-Cycle-Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma","volume":"28","author":"Yoshida","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/IGC.0000000000000720","article-title":"Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database","volume":"26","author":"Hosh","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989\u20131999","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/ijgc-2022-004204","article-title":"Prognostic factors in patients with uterine sarcoma: The SARCUT study","volume":"33","author":"Zapardiel","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2559.2009.03231.x","article-title":"Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients","volume":"54","author":"Abeler","year":"2009","journal-title":"Histopathology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Khan, S.R., Soomar, S.M., Asghari, T., Ahmed, A., and Moosajee, M.S. (2023). Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years\u2019 clinical experience from a tertiary care center in Pakistan. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11000-3"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.18.01990","article-title":"Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma","volume":"37","author":"Tomao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/hum.2017.206","article-title":"Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy","volume":"29","author":"Xia","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Huang, X., and Peng, P. (2022). Hormone Therapy Reduces Recurrence in Stage II-IV Uterine Low-Grade Endometrial Stromal Sarcomas: A Retrospective Cohort Study. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.922757"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2011.11.009","article-title":"Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma","volume":"124","author":"Leitao","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gore.2018.11.001","article-title":"A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS)","volume":"27","author":"Slomovitz","year":"2019","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4143\/crt.2024.343","article-title":"Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcomas","volume":"57","author":"Song","year":"2025","journal-title":"Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"107126","DOI":"10.1016\/j.phrs.2024.107126","article-title":"CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer","volume":"202","author":"Lv","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12943-023-01884-x","article-title":"A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better","volume":"22","author":"Djureinovic","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/apc.2019.11.01","article-title":"Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma","volume":"2","author":"Saung","year":"2019","journal-title":"Ann. Pancreat. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1689\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T04:24:35Z","timestamp":1779596675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111689"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111689","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}